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eHealth and mobile health (mHealth)
Information and communication technologies (ICT) 
offer patients and healthcare providers new ways to 
improve wellness, practice prevention and reduce suffering 
from diseases. eHealth is defined by the World Health 
Organization as “the use of ICT for health” (1). ICT represents 
a new opportunity to enhance care, which is also true for 
the field of Urology. The term eHealth was first used in 
1999 and has become a neologism, i.e., an umbrella term 
that includes many items ranging from the infrastructure 
to access the images from a computer tomography scan via 
the picture archiving and communication system (PACS), 
to the implementation of telemedicine, and even the use of 
augmented reality or machine learning algorithms (2). 
In 2012 the European Commission published an eHealth 
Action Plan 2012–2020 as a roadmap to empower patients 
and healthcare workers, to link up devices and technologies, 
and to invest in research towards the personalized medicine 
of the future (3). The European Commission feels eHealth 
holds great potential as “it can benefit citizens, patients, 
health and care professionals, as well as health organizations and 
public authorities”. When eHealth is applied effectively, it 
is thought to deliver more personalized ‘citizen-centric’ 
healthcare, i.e., healthcare that is more targeted, effective 
and efficient and helps reduce errors, as well as the 
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length of hospitalization. It furthermore facilitates socio-
economic inclusion and equality, quality of life and patient 
empowerment through greater transparency, access to 
services and information, and the use of social media for 
health (3). 
mHealth is a subset of eHealth which can be characterized 
as “mobile wireless technologies for public health” (1). Because of 
its ease of use and broad acceptance, mHealth is considered a 
valuable tool in the implementation of patient-centered care 
(patient-reported preferences, experiences and outcomes), 
which has become a goal of contemporary healthcare systems 
and international standards (4). There is evidence of successful 
implementations of mHealth in different contexts, ranging 
from mobile phone-based clinical guidance for rural health 
providers in India, to apps that help pregnant women with 
gestational diabetes in Oxford (5,6). Moreover, its demographic 
reach transcends generations with various successful examples, 
including the promotion of physical activity and its acceptance 
by both young and older adults (7,8). 
One of the most popular aspects of mHealth are 
smartphone applications (“apps”). Currently, there are 
almost 300,000 mHealth apps available in the Apple App 
Store and Google Play Store (9). These two virtual stores 
cover more than 90% of the smartphone ecosystem (9). 
mHealth interventions can furthermore be implemented 
using basic phones (e.g., sending health advice via SMS), 
tablets (e.g., replacing bedside paper-based medical charts) 
and wearables (e.g., fitness monitoring with an Apple 
Watch). The total mHealth market revenue alone is 
expected to reach US $26 billion at the end of 2017 (9). 
Advantages and concerns related to the use of 
eHealth and mHealth
eHealth and mHealth can be useful for treating patients, 
but also for conducting research, educating professionals, 
monitoring public health, and tracking chronic diseases. 
They are thought to be cost-effective alternatives to more 
traditional face-to-face ways of providing medical care and 
therefore hold a great potential in the ever growing world of 
healthcare expenditure. mHealth has the ability to provide 
access to healthcare as well as timely sharing of data. Real-
time monitoring devices can gather live data from sensors 
and send inputs into a mobile medical app on a smartphone, 
a server or network to support clinical decision making. It 
does so regardless of geographical barriers, environmental 
circumstances and traditional infrastructures; currently 
there are places where people are more likely to have access 
to a mobile phone than to clean water or electricity (10). 
However, to avoid harm, it is critical that, among other 
concerns, scientific accuracy, patient privacy and user safety 
of mHealth applications are assured. 
Literature has shown a lack of involvement of healthcare 
professionals in app development in all medical specialties, 
including Urology. This is concerning as it has also 
been proven that their participation and contribution in 
the elaboration of apps increases content accuracy, app 
downloads and buy-in (11-13). Because most mHealth apps 
are not considered medical devices by their developers, 
they bypass strict regulation such as the European Union 
MEDDEV 2.1/6 (July 2016) “Guidelines on the qualification 
and classification of stand alone software used in healthcare within 
the regulatory framework of medical devices”, which states: “it is 
necessary to clarify that software in its own right, when specifically 
intended by the manufacturer to be used for one or more of the 
medical purposes set out in the definition of a medical device, is a 
medical device”. Few mHealth apps have been scientifically 
reviewed and/or approved by the European Medicines 
Agency or the USA Food and Drug Administration (14). 
This can have serious clinical consequences. As an example, 
in Dermatology, where smartphones are commonly used as 
clinical diagnostic tools—and therefore would be a medical 
device according to MEDDEV for which certification is 
necessary—an app that claimed to quantify skin cancer risk 
mislabeled 80% of textbook melanomas (15,16).
Because of the intrinsic nature of eHealth and, in 
particular mHealth, sensitive health data can be exchanged 
via wireless networks, which raises new safety concerns. 
Cyber security attacks are a contemporary concern: 
in a recent European Union Agency for Network and 
Information Security (ENISA) study, two thirds of the 
European Member States considered healthcare a critical 
sector (17). Therefore, measures should be taken to protect 
the data integrity, assure data protection and guarantee 
patient confidentiality. This can be assured in various 
ways, depending on the specific scenario, but may include 
cryptography (i.e., saving the information in a coded form), 
role-based access control (i.e., each user can only read 
and/or edit certain data, according to his/her professional 
role) or watermarking (i.e., embedding hidden medical 
data in medical images). In the European Union the Data 
Protection Regulation Act (EU2016/679) reforms the data 
protection rules on processing personal data of natural 
persons and on the free movement of such data. Together 
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with the MEDDEV 2.1/6 (July 2016) guideline, they form 
some sort of a European Union legal framework, providing 
some legal clarity on the status of health and wellbeing 
mobile applications. Because of the legal aspects related to 
patient security and data privacy governments are, based 
on the European Union legal framework, expected to 
introduce clear cyber security guidelines for the protection 
of eHealth infrastructures and services. Therefore, eHealth 
providers should assure that they respect these guidelines. 
Finally, the importance of cyber security training and 
specific recommendations should also be promoted among 
healthcare organizations and users.
Implementation of eHealth and mHealth—
clinicians and patients perspective
The integration of eHealth and mHealth into clinical 
practice has to be tailored to a specific goal and try to meet 
the patients’ and the healthcare professionals’ expectations. 
Research in the Netherlands has shown that the uptake 
of eHealth and mHealth applications is only to increase 
when applications are built with a vision and fulfil a certain 
necessity (18). From the patients’ perspective, in the specific 
case of prostate cancer, depending on his level of comfort 
with technology and willingness for eHealth/mHealth 
interactions, this can range from a simple appointment 
reminder sent via SMS to virtual evaluation as an alternative 
to in-person interaction. For the healthcare professional, 
eHealth and mHealth may be another opportunity to 
provide care, as a complement to the standard clinical 
appointment or perhaps even as a replacement to some 
outpatient visits. 
As with social media, caution is needed in the interaction 
between the clinician and patient through eHealth or 
mHealth. To assure a high level of professionalism and 
setting boundaries, scientific organizations are issuing 
guidelines and publishing recommendations on how 
to communicate with patients through eHealth and 
mHealth (19). For example, it is recommended that all 
direct patient-professional contact should take place during 
regular working hours (19). 
eHealth and mHealth in prostate cancer and 
active surveillance
Prostate cancer has the second highest incidence among 
men worldwide and is a concern in many healthcare 
systems. Several studies have been designed to improve 
the current care paradigm, and the European Randomized 
study of Screening for Prostate Cancer (ERSPC) showed 
that mortality could be lowered via screening. After 13 years 
of follow-up, the results confirm a reduction of 21% in 
prostate cancer mortality attributable to screening with 
prostate specific antigen (PSA). The absolute risk reduction 
of death from prostate cancer at 13 years was 0.11 per 
1,000 person-years or 1.28 per 1,000 men randomized, 
which is equivalent to 1 prostate cancer death averted per 
781 screened men and 1 per 27 diagnosed men. Moreover, 
there was a substantial increased absolute effect compared 
with findings after 9- and 11-year of follow-up (20).
The ERSPC study has also shown that population-
based screening would lead to overdiagnosis (i.e., detecting 
cancers that would not cause symptoms or death), and 
consequently overtreatment (i.e., overdiagnosed cancers 
that are treated and their possible side-effects, namely 
incontinence and erectile dysfunction) (21). While research 
is focusing on how to improve the screening algorithm and 
reduce the rate of overdiagnosis, active surveillance was 
developed as an alternative to immediate radical treatment. 
Active surveillance aims to delay or completely avoid 
unnecessary treatment of potentially indolent tumors (e.g., 
Gleason 3+3) and avoid treatment related side-effects, and 
consequently preserve the patients’ quality of life. 
With active surveillance, patients with apparent low-
risk tumors enter a strict follow-up schedule consisting of 
clinical visits, PSA, multi-parametric magnetic resonance 
imaging (mpMRI) and re-biopsy, to ensure that if there is 
disease progression (i.e., clinically significant prostate cancer 
Gleason ≥3+4) the patient can switch to active treatment 
while the disease is still in a “curable” stage (i.e., before the 
cancer has grown or spread beyond control).
Rotterdam prostate cancer risk calculator 
(RPCRC)
One way of reducing overdiagnosis is to apply risk stratification 
in the prostate cancer diagnostic phase. Based on data from 
3,624 previously unscreened men and 2,896 men with a 
previous negative prostate biopsy in ERSPC Rotterdam, the 
RPCRC nomogram was developed. The RPCRC predicts 
the risk of a biopsy-detectable prostate cancer and also of 
potentially high-risk prostate cancer (Gleason score ≥7 and 
clinical stage >T2b). The different RPCRC algorithms, 
combining information on PSA level, previous negative 
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prostate biopsy, digital rectal examination (DRE), prostate 
volume measurement, and transrectal ultrasonography 
(TRUS), provide an increasingly accurate risk estimation 
[area under the curve (AUC)]. In previously unscreened 
men, the AUCs ranged from 0.69 to 0.79 for any prostate 
cancer, and from 0.74 to 0.86 for serious prostate 
cancer (22). In the previously screened group (men with at 
least one previous negative prostate biopsy), applying the 
same models, AUCs ranged from 0.62 to 0.69 for predicting 
prostate cancer and from 0.72 to 0.81 for predicting serious 
prostate cancer (22). By applying the RPCRC, 30–35% of 
prostate biopsies are averted, while missing only a small 
percentage of cancers and none of the high risk prostate 
cancers (22). The RPCRC risk predictions aid in decreasing 
the rate of overdiagnosis and overtreatment, and has been 
externally validated multiple times, confirming its good 
predictive capability (23). 
The nomogram was designed into a graphical device and 
published online (www.prostatecancer-riskcalculator.com) in 
2007 (24). After its publication, an implementation study in 
five Dutch hospitals was initiated to assess the value of the 
RPCRC in daily clinical practice and whether the RPCRC 
recommendations were followed by urologists and patients. 
In 83% of cases, both urologists and patients complied with 
the RPCRC recommendation (25). If a man is diagnosed 
with prostate cancer, risk calculator five calculates the 
chance of having an indolent prostate cancer. An indolent 
tumor is a cancer that may not require immediate treatment. 
Such a man can start and continue active surveillance as 
long as no upgrading is seen. When the probability of 
having indolent disease was >70%, active surveillance was 
recommended, and active treatment otherwise. 82% of 
patients with an active surveillance recommendation were 
compliant with that recommendation while 29% of patients 
with an active treatment recommendation chose active 
surveillance instead (26).
Both studies indicate that the RPCRC is a valuable 
eHealth tool which can inform decision-making and 
decrease the rate of overdiagnosis and potential subsequent 
overtreatment. Furthermore, the RPCRC has been 
externally validated to assess its capabilities in other patient 
cohorts and healthcare systems. Results confirm the good 
discriminative ability of the risk calculator and show how 
such an eHealth tool positively influences cross border 
healthcare, which is one of the pillars of the European 
Unions’ eHealth Action Plan 2012–2020. 
Validation studies confirm that the use of the RPCRC 
should be favored in the decision of whether or not to 
perform prostate biopsies over the conventional diagnostic 
pathway. This advice has been incorporated into the 
European Association of Urology prostate cancer guideline, 
as well as the Dutch General Practitioners guideline. It 
confirms that the RPCRC is an example of an eHealth tool 
with a vision, a true added value in daily clinical practice 
that positively influences cross border healthcare.  
To increase the usability and accessibility of the web-
based RPCRC, it has been redesigned into an app, using 
the same algorithms as for the available web-based risk 
calculators (Figure 1). While the web-based RPCRC was 
working with a graphical display, the app uses a decision 
tree structure. The amount of information available induces 
which algorithm is used. Ninety-two participants, including 
urologists, medical students, and general practitioners, 
evaluated the usability of the app through the Post-Study 
System Usability Questionnaire (PSSUQ, developed by 
IBM). Scores on system usefulness ranged from 88–98%, 
information quality from 78–92%, and interface quality 
from 80–95% (27). These results show that overall the 
participants were satisfied with the usability of the app. 
In 2015, the RPCRC app won the British Journal of 
Urology International award for Best Urology App, which 
was presented at the American Urological Association 
Annual Meeting. In clinical practice, numerous urologists 
worldwide use the RPCRC-app on a daily basis. 
The Prostate cancer Research International 
Active Surveillance (PRIAS) study
Men diagnosed with low-risk prostate cancer (PSA ≤10, 
Gleason 3+3, T1c-T2a) can choose between active 
treatment and active surveillance. In 2006 the PRIAS study 
was initiated to validate the management of prostate cancer 
with active surveillance. More information on the PRIAS-
protocol can be found on www.prias-project.org. 
The PRIAS study is an entirely web-based study. 
Physicians can log in the website to enter patient inclusion 
and follow-up data. Urological clinical practice can benefit 
from the use of this tool; the follow-up data entered by 
the physician generates a graphical display of the PSA 
measurements and PSA-doubling time. Furthermore, a 
recommendation on whether the patient should continue 
on active surveillance or switch to curative treatment is 
automatically presented. Such information facilitates direct 
evidence-based decision making for the patient and the 
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physician when considering active surveillance (28).
As said, active surveillance is a monitoring strategy 
and consists of a range of clinical visits including PSA 
measurement, mpMRI, and re-biopsy. The low-risk nature 
of the tumor combined with the long follow-up trajectory 
makes it more of a chronic condition. The diagnosis of 
disease and the medical mills they end up in can cause 
patients to feel they have lost control over the situation and 
their bodies. This may cause restlessness for patients and 
their spouses/partners/families and a feeling of uncertainty. 
Within the PRIAS study the ‘Follow MyPSA’-app is being 
developed to guide patients. Such an eHealth application 
provides patients with the opportunity to monitor their 
disease, plan and manage appointments and questions for 
their urologists. It is hypothesized that the use of such a tool 
will encourage active participation and can have a positive 
effect on the quality of life of the patient. Furthermore, it 
can improve the quality of care as it can focus on patients’ 
needs more specifically (29).   
Urology apps
The RPCRC (website and app), the PRIAS website and 
the ‘Follow MyPSA’-app are three examples of eHealth 
applications in the field of Urology. In 2015, Pereira-
Azevedo et al. reviewed the number of Urology apps 
available in the Apple App Store and Google Play Store. 
They identified 150 unique Urology apps, of which 
34 were urological cancer apps. It should be noted that 
these 150 Urology apps represented less than 1% of the 
total number of smartphone medical apps available. At the 
time, there seemed to be an untapped potential for Urology 
apps, especially taking into account that there were more 
breast cancer apps (n=178; 118 for Android, 59 for iOS) 
than all available Urology apps in total (30). 
For the current article, an updated review of urology apps 
available in the Apple App Store and Google Play Store was 
performed, using the methods previously described (30). 
One hundred and seventy-six unique urology apps were 
found (+17%); 67 (38%) for Android, 62 (35%) for iOS, and 
47 (27%) available on both stores (Table 1). Only 20 (11%) 
apps were related to prostate cancer, and the majority (60%) 
were developed with a healthcare professional (Figure 2): 
Briganti Nomogram, CPC Risk Calculator, Follow MyPSA, 
IPCRC (Prostate Cancer Calculator), itsaMANTHING—
Prostate Cancer, iURO Prostate Pro, Partin Tables, PI-
RADS Prostate MRI, Prostate Cancer, Prostate Cancer 
Calculator, Prostate Cancer Clinical Risk Classification 
Tool, Prostate Cancer Counselor, Prostate Cancer Imaging, 
Prostate Cancer Update, Prostate Health, Prostate In 
Focus, Prostate International, Prostate Pal 3, RPCRC, and 
Understanding and Treating Prostate Cancer. Even though 
there was in increase in the number of apps, there still 
seems to persist an untapped potential for the participation 
of the urological community in app development, as 1 in 
4 apps were developed without a healthcare professional, 
which is slightly worse than in 2015 (30).
Conclusions
eHealth and mHealth are becoming ubiquitous in our day-
to-day life. Possible use in Urology ranges from educational, 
clinical or surgical purposes, and may include such diverse 
tools as health promoting apps, electronic diaries that 
aid in treatment monitoring or augmented reality apps. 
The future will include the use of innovative and ground-
breaking ICT solutions and the challenge will be to define 
a clear vision for them. To increase the uptake of eHealth 
applications, it is important that healthcare professionals are 
involved in their design, assuring usability, and also their 
development, promoting evidence-based views. To reach 
their full potential healthcare apps must integrate seamlessly 
into urological practice, while fulfilling the clinical needs of 
professionals and patients.
Figure 1 Initial screen of the Rotterdam Prostate Cancer Risk 
Calculator app: “What is your PSA level, in ng/mL?”
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Table 1 Currently available Urology apps in the Google Play and Apple App stores
App name Mobile platform Healthcare professional involvement
American Urological Association Journals Apple App Store Yes
ASMIUA 2017 Google Play Store Yes
Astellas UroLog Apple App Store No
AUA 2014 Annual Meeting Google Play Store Yes
AUA Annual Meeting Apps Both Yes
AUA Guidelines at a Glance Google Play Store Yes
AUA Journals Google Play Store Yes
AUA Medical Student Curriculum Google Play Store Yes
AUA Member Search Both Yes
AUA Men’s Health Checklist Both Yes
AUA University Both Yes
BAUN16 Apple App Store Yes
BAUS 2016 Apple App Store Yes
BAUS 2017 Google Play Store Yes
Bedwetting solutions Google Play Store No
Bedwetting Trainer Google Play Store Yes
Besins UroMedica Google Play Store Yes
BJUI Journal Apple App Store Yes
BJUI Knowledge Google Play Store Yes
Bladder Pal 2 Apple App Store Yes
BMC Urology Both Yes
Brazial Journal of Urology Both Yes
Briganti Nomogram Google Play Store No
BSC Urology Events Apple App Store No
CalcuLithiasis Apple App Store Yes
Canadian Urological Association Apple App Store Yes
CKD Chronic Kidney Disease Google Play Store Yes
Clinicians Drug Reference 2016 Google Play Store Yes
CPC Risk Calculator Google Play Store Yes
CUA Google Play Store Yes
CURE-UAB Both Yes
DoubleJTracker Apple App Store Yes
drawMD® Patient Education Both Yes
DutasT Both Yes
E-UROLOGICAL TOOLS Google Play Store Yes
EAU Events Both Yes
Table 1 (continued)
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Table 1 (continued)
App name Mobile platform Healthcare professional involvement
EAU Guidelines Both Yes
EAU Pocket Guidelines Google Play Store Yes
EAU16 Google Play Store Yes
EAUN15 Google Play Store Yes
EMUC 2016 Both Yes
EMUC 2017 Both Yes
ESPU Both Yes
Esurge Apple App Store No
European Urology Both Yes
European Urology Journals Google Play Store Yes
Exercise UI in Women Apple App Store No
Fertility and Sterility® Google Play Store Yes
Follow MyPSA Google Play Store Yes
Foundation Urology Google Play Store Yes
GeSRU Uro Emergency Google Play Store Yes
HapPee Time Google Play Store No
Human Body: Genitourinary System Trivia Apple App Store No
Human Body Parts: Kidneys Quiz Apple App Store No
Human Urinary System Quiz Apple App Store No
InformedUrology Both Yes
International Urogynecology Journal Both Yes
iP Voiding Diary Apple App Store No
IPCRC (Prostate Cancer Calculator) Google Play Store Yes
IPSS Prostate Score Apple App Store No
iReflux Risk Calculator Both No
itsaMANTHING—Prostate Cancer Both No
iURO Andrology Both Yes
iURO Andrology Pro Both Yes
iURO General Practicioner Pro Both Yes
iURO Kidney Lite Both Yes
iURO Kidney Pro Both Yes
iURO Oncology Both Yes
iURO Oncology Pro Both Yes
iURO Pelvic Floor Both Yes
iURO Pelvic Floor Pro Both Yes
iURO Prostate Pro Both Yes
Table 1 (continued)
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Table 1 (continued)
App name Mobile platform Healthcare professional involvement
Journal of Renal Care Apple App Store Yes
JUS—Journal of the Urological Surgery Google Play Store Yes
Kidney Cancer Google Play Store No
Kidney Cancer Planner Apple App Store No
Kidney Disease Assistant Apple App Store No
Kids’ Guide to Using a Catheter Apple App Store Yes
Learning Urology Quiz Both Yes
Male Infertility Microsurgery Apple App Store Yes
Medical Arts Xperience (“MAX”) Apple App Store Yes
Men’s App—Take care of men’s health Apple App Store Yes
Men’s Health Checklist Google Play Store Yes
Men’s Sexual Medicine PRO Apple App Store Yes
MSK Urologic Conference Google Play Store Yes
Neurourology and Urodynamics Apple App Store Yes
NMIBC Toolbox Apple App Store Yes
NUF2017 Both Yes
Nurse Urologic Registered Google Play Store Yes
Oral Board Study Guide Apple App Store Yes
Oxford HB Urology Both Yes
Partin Tables Apple App Store No
Pediatric Urologic Surgery QA Review Apple App Store No
Pediatric Urology Exam Review Apple App Store No
Perioperative Care Apple App Store Yes
PI-RADS Prostate MRI Google Play Store Yes
Practical Urology Both Yes
AUA Primary Care Guidelines for Urology Apple App Store Yes
Prostate Cancer Google Play Store No
Prostate Cancer Calculator Google Play Store No
Prostate Cancer Clinical Risk Classification Tool Apple App Store Yes
Prostate Cancer Counselor Apple App Store No
Prostate Cancer Imaging Apple App Store Yes
Prostate Cancer Update Apple App Store No
Prostate Health Google Play Store No
Prostate In Focus Google Play Store Yes
Prostate International Both Yes
Prostate Pal 3 Apple App Store Yes
Table 1 (continued)
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Table 1 (continued)
App name Mobile platform Healthcare professional involvement
Renal & Urology News Both Yes
Renal Mass—Bosniak Google Play Store Yes
Reviews in Urology Apple App Store Yes
Rotterdam Prostate Cancer Risk Google Play Store Yes
Salvador Gil Vernet Collection of Urology Drawings Google Play Store Yes
Semi-Live Apple App Store Yes
Signs & Symptoms Urinay Incontinence Apple App Store No
SIU Academy® Both Yes
SIU2016 Apple App Store Yes
STOP UTI Google Play Store Yes
SUNA urologic Google Play Store Yes
Surgery Urologic Pediatric Google Play Store Yes
Surgery Urologic QA Review Google Play Store Yes
Szusicon2017 Google Play Store Yes
Testicular Cancer Staging Both No
The 5 Minute Urology Consult 3 Both Yes
Turkish Journal of Urology Apple App Store Yes
UAA 2017 Both Yes
UAA Congress 2016 Google Play Store Yes
Understanding and Treating Prostate Cancer Apple App Store Yes
Ureteral Stent Tracker System Both No
Urinary/Renal System Exam Review Apple App Store No
Uro Challenge Apple App Store Yes
UroBladderDiary Apple App Store No
Urocon 2017 Google Play Store Yes
UroLift® for BPH Apple App Store No
Urolithiasis Assist Google Play Store Yes
Urologic Oncology Both Yes
Urologic Surgery QA Review Apple App Store No
Urological Emergencies Both Yes
Urological Surgery Google Play Store Yes
Urological Ultrasound Google Play Store Yes
Urology Google Play Store No
Urology Apple App Store No
Urology—Medical Dictionary Google Play Store Yes
Urology Board Review Manual Apple App Store Yes
Table 1 (continued)
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Table 1 (continued)
App name Mobile platform Healthcare professional involvement
Urology Case Reports Both Yes
Urology Courses Google Play Store No
Urology Exam Review & Test Bank Apple App Store No
Urology Flashcards 2.0 Both Yes
Urology Flashcards 2018 Google Play Store No
Urology Glossary Google Play Store No
Urology Guide Google Play Store No
Urology Guidelines Primary Care Google Play Store Yes
Urology Lectures Google Play Store No
Urology Nation Both Yes
Urology NBI Atlas by Olympus Apple App Store Yes
Urology News Both Yes
Urology Planet Apple App Store Yes
Urology Procedures Google Play Store No
Urology Specialty Care Google Play Store Yes
Urology Study Google Play Store No
Urology Times Google Play Store Yes
Urology, the Gold Journal Both Yes
Urology, Courses Apple App Store Yes
USICON Google Play Store Yes
USICON 2014 Google Play Store Yes
USICON 2016 Apple App Store Yes
USICON 2017 Apple App Store Yes
USICON 2018 Apple App Store Yes
UTI Tracker Google Play Store Yes
Vasectomy Reversal Google Play Store No
Voiding Diary Google Play Store Yes
Volume Diary Apple App Store No
WCE 2014 Google Play Store Yes
WCE 2016 Apple App Store Yes
WCE 2017 Apple App Store Yes
What is Urology? Apple App Store Yes
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Figure 2 Percentage of healthcare professional involvement in app development.
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